Ren, S., Wang, X., Han, B., Pan, Y., Zhao, J., Cheng, Y., et al. (2024) First-Line Treatment with Camrelizumab Plus Famitinib in Advanced or Metastatic NSCLC Patients with PD-L1 TPS ≥ 1%: Results from a Multicenter, Open-Label, Phase 2 Trial. Journal for ImmunoTherapy of Cancer, 12, e007227.
https://doi.org/10.1136/jitc-2023-007227

has been cited by the following article:

• TITLE: Progress of Immunotherapy Combined with Anti-Angiogenesis Therapy in Lung Cancer

  AUTHORS: Chenyang Zuo, Jinyuan Xie, Meng Wang, Jun Cai, Qingqing Ye

  KEYWORDS: Immunotherapy, Anti-Angiogenic Therapy, Lung Cancer, Tumor Immune Microenvironment

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.9, September 23, 2024

  ABSTRACT: Lung cancer is the most prevalent and fatal cancer in China and even around the world, and many patients are found in the late stage of lung cancer. For the treatment of advanced lung cancer, in addition to traditional chemotherapy modalities, many emerging treatments are increasingly significant, such as immunotherapy, anti-angiogenic therapy, and targeted therapy. An increasing number of studies have now shown that anti-angiogenic therapy improves the immune microenvironment by enhancing tumor immunity through normalization of tumor vessels. Immunization combined with anti-angiogenic therapy can exert synergistic effects and improve the prognosis of patients. This article summarizes the extent of benefit, current clinical study data, and future prospects of immunotherapy combined with anti-angiogenic agents in the treatment of advanced NSCLC.